United Therapeutics Corp reports 2Q 2008 financial results. [5 tables in original article].

United Therapeutics Corp announced its results of operations for 2Q ended Jun 2008. Total revenues for 2Q 2008 were $68.6 M, (+32.3% over $51.8 M in 2Q 2007). Net income for 2Q 2008 was $14.3 M, or $0.63/basic share, (net income of $5.8 M, or $0.28/basic share, in 2Q 2007). The increases in revenues and gross margins corresponded to the growth in sales of lead product, Remodulin. Research and development expenses for 2Q 2008 were $19.141 M (+6.5% over $17.97 M in 2Q 2007). United Therapeutics is a biotechnology company focused on the development and commercialisation of unique products …